May Su's Insider Trades & SAST Disclosures
May Su's most recent trade in Roivant Sciences Ltd was a trade of 689,495 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Dec. 23, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern May Su.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Roivant Sciences Ltd | Mayukh Sukhatme | Director, Pres&Chief Investment Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2024 | 689,495 | 15,224,363 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Mayukh Sukhatme | Director, Pres&Chief Investment Officer | Sale of securities on an exchange or to another person at price $ 12.01 per share. | 23 Dec 2024 | 689,495 | 18,836,547 | - | 12.0 | 8,280,835 | Common Shares |
| Roivant Sciences Ltd | Mayukh Sukhatme | Director, Pres&Chief Investment Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 23 Dec 2024 | 689,495 | 19,526,042 | - | 3.9 | 2,654,556 | Common Shares |
| Roivant Sciences Ltd | Mayukh Sukhatme | Director, Pres&Chief Investment Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 23 Dec 2024 | 185,946 | 19,022,493 | - | 3.8 | 715,892 | Common Shares |
| Roivant Sciences Ltd | Mayukh Sukhatme | Director, Pres&Chief Investment Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2024 | 185,946 | 15,913,858 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Mayukh Sukhatme | Director, Pres&Chief Investment Officer | Sale of securities on an exchange or to another person at price $ 12.00 per share. | 23 Dec 2024 | 185,946 | 18,836,547 | - | 12 | 2,231,352 | Common Shares |
| Roivant Sciences Ltd | Mayukh Sukhatme | Director, Pres&Chief Investment Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 23 Dec 2024 | 10,796 | 18,847,343 | - | 3.9 | 41,565 | Common Shares |
| Roivant Sciences Ltd | Mayukh Sukhatme | Director, Pres&Chief Investment Officer | Sale of securities on an exchange or to another person at price $ 12.00 per share. | 23 Dec 2024 | 10,796 | 18,836,547 | - | 12 | 129,552 | Common Shares |
| Roivant Sciences Ltd | Mayukh Sukhatme | Director, Pres&Chief Investment Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2024 | 10,796 | 16,099,804 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Mayukh Sukhatme | Director, Pres&Chief Investment Officer | Sale of securities on an exchange or to another person at price $ 12.05 per share. | 18 Dec 2024 | 412,584 | 18,836,547 | - | 12.0 | 4,971,637 | Common Shares |
| Roivant Sciences Ltd | Mayukh Sukhatme | Director, Pres&Chief Investment Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Dec 2024 | 412,584 | 16,110,600 | - | - | Stock Option (Right to Buy) | |
| Roivant Sciences Ltd | Mayukh Sukhatme | Director, Pres&Chief Investment Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 18 Dec 2024 | 412,584 | 19,249,131 | - | 3.8 | 1,588,448 | Common Shares |
| Roivant Sciences Ltd | Mayukh Sukhatme | Director, Pres&Chief Investment Officer | Other type of transaction at price $ 12.21 per share. | 03 Dec 2024 | 3,651,985 | 18,836,547 | - | 12.2 | 44,572,477 | Common Shares |
| Roivant Sciences Ltd | Mayukh Sukhatme | Director, Pres&Chief Investment Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2024 | 17,000,000 | 22,488,532 | - | 0 | Common Shares | |
| Roivant Sciences Ltd | Mayukh Sukhatme | Director, Pres&Chief Investment Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2024 | 1,836,547 | 5,488,532 | - | 0 | Common Shares | |
| Onto Innovation Inc. | May Su | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2024 | 809 | 5,109 (0%) | 0% | 0 | Common Stock | |
| Roivant Sciences Ltd | Mayukh Sukhatme | Director, Pres&Chief Investment Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Mar 2024 | 1,856,163 | 0 | - | - | Capped Value Appreciation Rights | |
| Roivant Sciences Ltd | Mayukh Sukhatme | Director, Pres&Chief Investment Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Mar 2024 | 729,081 | 4,018,196 | - | - | Common Shares | |
| Roivant Sciences Ltd | Mayukh Sukhatme | Director, Pres&Chief Investment Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.54 per share. | 30 Mar 2024 | 366,211 | 3,651,985 | - | 10.5 | 3,859,864 | Common Shares |
| Roivant Sciences Ltd | Sukhatme Mayukh | Pres&Chief Investment Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2023 | 159,100 | 1,856,163 | - | - | Capped Value Appreciation Rights | |
| Roivant Sciences Ltd | Mayukh Sukhatme | Pres&Chief Investment Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2023 | 71,365 | 3,289,115 | - | - | Common Shares | |
| Roivant Sciences Ltd | Sukhatme Mayukh | Pres&Chief Investment Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Dec 2023 | 28,411 | 1,306,889 | - | - | Capped Value Appreciation Rights | |
| Roivant Sciences Ltd | Mayukh Sukhatme | Pres&Chief Investment Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Aug 2023 | 53,033 | 2,068,296 | - | - | Capped Value Appreciation Rights | |
| Roivant Sciences Ltd | Mayukh Sukhatme | Pres&Chief Investment Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Aug 2023 | 22,565 | 3,189,960 | - | - | Common Shares | |
| Roivant Sciences Ltd | Mayukh Sukhatme | Pres&Chief Investment Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jul 2023 | 106,067 | 2,121,329 | - | - | Capped Value Appreciation Rights | |
| Roivant Sciences Ltd | Mayukh Sukhatme | Pres&Chief Investment Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jul 2023 | 43,212 | 3,167,395 | - | - | Common Shares | |
| Roivant Sciences Ltd | Mayukh Sukhatme | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 May 2023 | 318,199 | 2,227,396 | - | - | Capped Value Appreciation Rights | |
| Roivant Sciences Ltd | Mayukh Sukhatme | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 May 2023 | 99,458 | 3,124,183 | - | - | Common Shares | |
| Onto Innovation Inc. | May Su | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 May 2023 | 2,200 | 4,300 (0%) | 0% | 0 | Common Stock | |
| Onto Innovation Inc. | May Su | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2022 | 2,100 | 2,100 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges